Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products-Reference-Cited by-同舟云学术

Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products

Published:2024-08-22 Issue:1 Volume:13 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Castenmiller Suzanne M.¹²,Kanagasabesan Nandhini¹²,Guislain Aurélie¹²,Nicolet Benoît P.¹²,van Loenen Marleen M.¹,Monkhorst Kim³,Veenhof Alexander A.F.A.⁴,Smit Egbert F.⁵⁶,Hartemink Koen J.⁴,Haanen John B.A.G.⁷⁸⁹,de Groot Rosa¹¹⁰,Wolkers Monika C.¹²^ORCID

Affiliation:

1. Sanquin Blood Supply, Division Research Immunotherapy, and Landsteiner Laboratory and Department of Experimental Immunology, Amsterdam University Medical Center, Amsterdam, Netherlands

2. Oncode Institute, Utrecht, The Netherlands

3. Department of Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AvL), Amsterdam, The Netherlands

4. Department of Surgery, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AvL), Amsterdam, The Netherlands

5. Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AvL), Amsterdam, The Netherlands

6. Department of Pulmonology, Leiden University Medical Center (LUMC), Leiden, The Netherlands

7. Division of Medical Oncology and Division of Molecular Oncology and Immunology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AvL), Amsterdam, The Netherlands

8. Department of Medical Oncology, Leiden University Medical Center (LUMC), Leiden, The Netherlands

9. Head of Melanoma Clinic, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

10. Department of Hematology, LUMC, Leiden, The Netherlands

Funder

intramural Sanquin research funds

Oncode Institute

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2024.2392898

Reference80 articles.

1. Adoptive cell transfer as personalized immunotherapy for human cancer

2. Adoptive cell therapy for the treatment of patients with metastatic melanoma

3. CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma

4. Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients

5. Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients